Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kaye

Showing results (701-710 of 740) with videos related to

Pageof 74
Sort By:
JAMA|February 28, 2018
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical TrialKeith S Kaye, Tanaya Bhowmick, Symeon Metallidis, et al.
Scientific Reports|July 29, 2025
A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilitiesCourtney L Luterbach, Dana K Pasquale, Heather I Henderson, et al.
American Journal of Infection Control|January 31, 2012
The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilitiesDror Marchaim, Teena Chopra, Christopher Bogan, et al.
Microbiology Spectrum|May 23, 2023
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumanniiHadas Kon, Amichay Hameir, Amir Nutman, et al.
Antimicrobial Agents and Chemotherapy|February 23, 2012
Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremiaKayoko Hayakawa, Dror Marchaim, Emily T Martin, et al.
Infectious Diseases and Therapy|October 2, 2018
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical TrialRichard G Wunderink, Evangelos J Giamarellos-Bourboulis, Galia Rahav, et al.
Infection Control and Hospital Epidemiology|April 9, 2014
Introduction to "A Compendium of Strategies To Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 updates"Deborah S Yokoe, Deverick J Anderson, Sean M Berenholtz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancerM J Piccart, K Bertelsen, G Stuart, et al.
Infection Control and Hospital Epidemiology|September 30, 2014
Introduction to "A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates"Deborah S Yokoe, Deverick J Anderson, Sean M Berenholtz, et al.
Journal of the National Cancer Institute|May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsM J Piccart, K Bertelsen, K James, et al.
Pageof 74

Showing results (701-710 of 740) with videos related to

Sort By:
Pageof 74
JAMA|February 28, 2018
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical TrialKeith S Kaye, Tanaya Bhowmick, Symeon Metallidis, et al.
Scientific Reports|July 29, 2025
A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilitiesCourtney L Luterbach, Dana K Pasquale, Heather I Henderson, et al.
American Journal of Infection Control|January 31, 2012
The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilitiesDror Marchaim, Teena Chopra, Christopher Bogan, et al.
Microbiology Spectrum|May 23, 2023
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumanniiHadas Kon, Amichay Hameir, Amir Nutman, et al.
Antimicrobial Agents and Chemotherapy|February 23, 2012
Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremiaKayoko Hayakawa, Dror Marchaim, Emily T Martin, et al.
Infectious Diseases and Therapy|October 2, 2018
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical TrialRichard G Wunderink, Evangelos J Giamarellos-Bourboulis, Galia Rahav, et al.
Infection Control and Hospital Epidemiology|April 9, 2014
Introduction to "A Compendium of Strategies To Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 updates"Deborah S Yokoe, Deverick J Anderson, Sean M Berenholtz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancerM J Piccart, K Bertelsen, G Stuart, et al.
Infection Control and Hospital Epidemiology|September 30, 2014
Introduction to "A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates"Deborah S Yokoe, Deverick J Anderson, Sean M Berenholtz, et al.
Journal of the National Cancer Institute|May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsM J Piccart, K Bertelsen, K James, et al.
Pageof 74